@movewellwithtrent: Retatrutide is getting a lot of attention right now, and for good reason. But most of what’s being shared online skips over the actual science. This isn’t just another GLP-1 receptor agonist like Semaglutide, or a dual agonist like Tirzepatide. Retatrutide is a triple agonist that targets GLP-1, GIP, and glucagon receptors, which means it addresses appetite, insulin sensitivity, and energy expenditure at the same time. In the Phase 2 trial, participants were placed on weekly doses ranging from 1 mg up to 12 mg. Weight loss was dose-dependent and extremely impressive across the board: 1 mg: 8.7% 4 mg: 17.1% (average of 2 subgroups) 8 mg: 22.8% (average of 2 subgroups) 12 mg: 24.2% Placebo: 2.1% For comparison, an open-label Semaglutide group lost 18.7%. Beyond weight loss, participants also saw improvements in blood pressure, insulin sensitivity, fasting glucose, and lipid profiles. Even more notable—72% of people with prediabetes returned to normoglycemia by week 48. Of course, this isn’t without side effects. Like other incretin-based therapies, GI symptoms such as nausea and diarrhea were common, especially during the dose escalation phase. The trial addressed this by using a slow titration starting at 1-2 mg per week. Retatrutide is still in clinical trials and not approved for use. This is for educational purposes only. As a licensed chiropractor with degrees in Exercise Science and Human Biology and as a Certified Strength and Conditioning Specialist I share this to help cut through the noise. My goal isn’t to hype peptides, it’s to educate, so you can make informed decisions and avoid guesswork. If you want help understanding how peptides could fit into your strategy, or what stacks make sense based on your goals, you can book a consult through the link in my bio. #retatrutide #peptidetherapy #tirzepatide #semaglutide #glp1 #glp1agonist #obesityresearch

Dr. Trent Ashby, DC, CSCS

Open In TikTok:

Region: US

Wednesday 16 July 2025 20:08:49 GMT